Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation

Journal of Nuclear Medicine

Volumn 49, Issue 4, 2008, Pages 550-556

  Zellweger, Michael J ^a   Kaiser, Christoph ^a   Rocca, Hans Peter Brunner La ^a   Buser, Peter T ^a   Osswald, Stefan ^a   Weiss, Philipp ^a   Mueller Brand, Jan ^a   Pfisterer, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Coronary artery disease; Late stent thrombosis; Prognosis; Restenosis; Revascularization; Stent

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE; HEART SCINTISCANNING; HUMAN; IMPLANTATION; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; STATISTICAL SIGNIFICANCE; SYMPTOM; THROMBOSIS;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROGNOSIS;

EID: 42149126722     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.046771     Document Type: Article

References (20)

1. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989-997.
2. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimuseluting stents with bare-metal stents. N Engl J Med. 2007;356:1030-1039.
3. Indolfi C, Pavia M, Angelillo IF. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am J Cardiol. 2005;95:1146-1152.
4. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006;354:483-495.
5. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-1029.
6. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008.
7. Zellweger MJ, Weinbacher M, Zutter AW, et al. Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. J Am Coll Cardiol. 2003;42:33-40.
8. Pfisterer M, Rickenbacher P, Kiowski W, Muller-Brand J, Burkart F. Silent ischemia after percutaneous transluminal coronary angioplasty: incidence and prognostic significance. J Am Coll Cardiol. 1993;22:1446-1454.
9. Giedd KN, Bergmann SR. Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention. J Am Coll Cardiol. 2004;43:328-336.
10. Ruygrok PN, Webster MW, de Valk V, et al. Clinical and angiographic factors associated with asymptomatic restenosis after percutaneous coronary intervention. Circulation. 2001;104:2289-2294.
11. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet. 2005;366:921-929.
12. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: summary article - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention). Circulation. 2006;113:156-175.
13. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): executive summary - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation. 2001;103:3019-3041.
14. Berman DS, Kiat H, Friedman JD, et al. Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study. J Am Coll Cardiol. 1993;22:1455-1464.
15. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to update the 1997 exercise testing guidelines). J Am Coll Cardiol. 2002;40:1531-1540.
16. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: executive summary - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC committee to revise the 1995 guidelines for the clinical use of cardiac radionuclide imaging). J Am Coll Cardiol. 2003;42:1318-1333.
17. Zellweger MJ, Tabacek G, Zutter AW, et al. Evidence for left ventricular remodeling after percutaneous coronary intervention; effect of percutaneous coronary intervention on left ventricular ejection fraction and volumes. Int J Cardiol. 2004;96:197-201.
18. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-542.
19. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-2591.
20. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351.